in ,

The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings


Biotech stocks continued to move southward in the week ended March 5, as the broader market extended its sell-off. Though light on news, the week did witness earnings releases from smaller biopharma companies, coronavirus vaccine program updates, mixed FDA rulings and clinical readouts.

Morphic Holding Inc (NASDAQ:MORF) was among the biggest gainers of the week after the company reported a positive early-stage readout in inflammatory bowel disease patients.

M&A momentum continued, as Amgen Inc. (AMGN) announced a deal to buy Five Prime Therapeutics, Inc. (NASDAQ:FPRX) in an $1.9-billion all-cash deal.

Here are the key catalysts for the unfolding week:


Chardan’s 3rd Annual Microbiome Medicines Summit: March 8

H.C. Wainwright Global Life Sciences Conference: March 9-11

Barclays Global Healthcare Conference: March 9-11

15th International Conference on Alzheimer’s and Parkinson’s disease: March 9-14

Clinical Readouts

Prothena Corporation plc (NASDAQ:PRTA) will present at the Alzheimer’s and Parkinson’s disease conference new preclinical data on a treatment for Alzheimer’s disease. The treatment targets an anti-tau antibody, which is thought to play a role in the disease. The company says targeting a certain antibody called a novel epitope with PRX005 has shown superior results. The presentation is scheduled for Thursday, March 11, between 7:30 a.m. and 7:45 a.m.



Minerva Neurosciences, Inc. (NASDAQ:NERV) (before the market open)

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) (after the close)

Castle Biosciences, Inc. (NASDAQ:CSTL) (after the close)

SI-BONE, Inc. (NASDAQ:SIBN) (after the close)

Avadel Pharmaceuticals plc (NASDAQ:AVDL) (after the close)

Related Link: Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates


Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) (before the market open)

Trevena, Inc. (NASDAQ:TRVN) (before the market open)

InspireMD, Inc. (NYSE:NSPR) (before the market open)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) (before the market open)

DarioHealth Corp. (NASDAQ:DRIO) (before the market open)

Gamida Cell Ltd. (NASDAQ:GMDA) (before the market open)

Evelo Biosciences, Inc. (NASDAQ:EVLO) (before the market open)

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (before the market open)

Aquestive Therapeutics, Inc. (NASDAQ:AQST) (after the close)

Brickell Biotech, Inc. (NASDAQ:BBI) (after the close)

Cytosorbents Corporation (NASDAQ:CTSO) (after the close)

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) (after the close)

MiMedx Group, Inc. (NASDAQ:MDXG) (after the close)

Inari Medical, Inc. (NASDAQ:NARI) (after the close)

Lyra Therapeutics, Inc. (NASDAQ:LYRA) (after the close)


Bio-Path Holdings, Inc. (NASDAQ:BPTH) (before the market open)

Harvard Bioscience, Inc. (NASDAQ:HBIO) (before the market open)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) (before the market open)

Clearside Biomedical, Inc. (NASDAQ:CLSD) (after the close)

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) (after the close)

Five Prime Therapeutics (NASDAQ:FPRX) (after the close)

Flexion Therapeutics, Inc. (NASDAQ:FLXN) (after the close)

Harpoon Therapeutics, Inc. (NASDAQ:HARP) (after the close)

Lantern Pharma Inc. (NASDAQ:LTRN) (after the close)

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) (after the close)

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (after the close)

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) (after the close)

OrthoPediatrics Corp. (NASDAQ:KIDS) (after the close)


Burning Rock Biotech Limited (NASDAQ:BNR) (before the market open)

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) (before the market open)

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (before the market open)

Achieve Life Sciences, Inc. (NASDAQ:ACHV) (after the close)

Capricor Therapeutics, Inc. (NASDAQ:CAPR) (after the close)

Lineage Cell Therapeutics, Inc. (NYSE:LCTX) (after the close)

Geron Corporation (NASDAQ:GERN) (after the close)

Chembio Diagnostics, Inc. (NASDAQ:CEMI) (after the close)

Ocular Therapeutix, Inc. (NASDAQ:OCUL) (after the close)

Nabriva Therapeutics plc (NASDAQ:NBRV) (after the close)

Related Link: Johnson & Johnson Secures Emergency Authorization For Its Single-Shot COVID-19 Vaccine

What do you think?


Leave a Reply

Your email address will not be published. Required fields are marked *



Microaggressions will ruin your employee engagement. The secret to a healthy culture is learning to build empathy.


COVID-19 Pandemic – The government presents its daily update